Comparative Pharmacology
Head-to-head clinical analysis: LOCHOLEST versus QUESTRAN LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCHOLEST versus QUESTRAN LIGHT.
LOCHOLEST vs QUESTRAN LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver.
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
4 grams (one packet or one level scoop) orally once or twice daily, with a maximum of 24 grams per day. Dose may be increased by 4 grams daily at weekly intervals as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing.
Not applicable; cholesteryamine resin is not absorbed systemically; half-life refers to GI transit time (~2-4 hours).
Primarily fecal (biliary) as unchanged drug; renal excretion <5%.
Primarily fecal (as resin-bound bile acids); less than 0.05% renally excreted unchanged.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant